AnaptysBio ANAB
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 93rd percentile, 5-year average -7.8x
#484 of 2992 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 85th percentile, 5-year average 21.4x
#5277 of 5330 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 7th percentile, 5-year average 29.4x
#4103 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 66.07 | – | 21.44 | 85% (pricier than usual) | #5277 of 5330 (1 = cheapest) |
| PE | 8.91 | 9.54 | -7.75 | 93% (pricier than usual) | #484 of 2992 (1 = cheapest) |
| PS | 5.92 | 11.59 | 29.45 | 7% (cheaper than usual) | #4103 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ANAB.
Sign in to join the discussion.